Paraneoplastic conditions may present secondary to urologic malignancy. Providers should perform thorough malignancy screening, including urologic cystoscopy, in patients presenting with paraneoplastic signs and no identified malignancy.
Oral retinoids, such as acitretin, may be used as an adjuvant treatment to treat paraneoplastic cutaneous symptoms. The definitive treatment is malignancy management.